11 October 2023 in British Journal of Haematology
Summary: Despite the efficacy of splenectomy for chronic immune thrombocytopenia (ITP), its considerable failure rate and its possible related complications prove the need for further research into potential predictors of response. The platelet sequestration site determined by 111In‐labelled autologous platelet scintigraphy has been proposed to predict splenectomy outcome, but without standardisation in clinical practice. Here, we conducted a single‐centre study by analysing a cohort of splenectomised patients with ITP in whom 111In‐scintigraphy was performed at La Paz University Hospital in Madrid to evaluate the predictive value of the platelet kinetic studies. We also studied other factors that could impact the splenectomy outcome, such as patient and platelet characteristics. A total of 51 patients were splenectomised, and 82.3% responded. The splenic sequestration pattern predicted a higher rate of complete response up to 12 months after splenectomy (p = 0.005), with 90% sensitivity and 77% specificity. Neither age, comorbidities, therapy lines nor previous response to them showed any association with response. Results from the platelet characteristics analysis revealed a significant loss of sialic acid in platelets from the non‐responding patients compared with those who maintained a response (p = 0.0017). Our findings highlight the value of splenic sequestration as an independent predictor of splenectomy response.
30 May 2025 in Haemophilia
Introduction: Patients with severe haemophilia A (HA) with no family history of haemophilia will be diagnosed upon their first bleeding event. Methods: Herein, we studied the effects of lack of family history in HA and the subsequent delay of diagnosis on bleeding pattern and early treatment, as well as on the risk of inhibitor development. For this purpose, data on 1237 severe HA patients with known family history (“positive” or “negative”), born between 2000 and 2022, were collected in 29 participating centres. Results: At diagnosis, 45.9% (554/1208) of patients had a positive family history of HA and 54.1% (654/1208) had a negative family history. A positive family history significantly shortened the time to diagnosis (8 months) and the treatment initiation (2 months). Prophylaxis was more frequently the first treatment in those with a positive family history compared to the negative family history group (21% vs. 13%). Bleeding was the main reason for first exposure day (ED) in both groups, but less frequently in the family history group than in those without a family history (67% vs. 80%). Positive family history was associated with fewer peak treatments at first five EDs (12% vs. 16%). In non‐inhibitor patients, bleeding occurred earlier in those with positive family history (9.2 months vs. 10.6 months). The inhibitor incidence was similar in both groups (33% vs. 30%), and a positive family history was associated with earlier inhibitor development (13 months vs. 15 months). Conclusion: The majority of patients presented without a family history of HA which led to a delayed diagnosis and treatment initiation.
26 May 2026 in Blood Reviews
Artificial intelligence (AI) is transforming morphological assessment in hematologic malignancies by enabling automated cell classification, detection of disease-specific features, and prediction of genetic alterations from blood and bone marrow smear images. Deep learning models have achieved expert-level performance in identifying malignant patterns, uncovering morphologic-molecular associations, and providing patient-level diagnoses through multiple instance learning approaches. This review summarizes recent advances in AI-driven morphological analysis across myeloid and lymphoid neoplasms, emphasizing their impact on diagnosis and disease classification. We further examine emerging evidence linking image-derived features, such as nuclear texture, cytoplasmic granularity, and spatial cell organization, to molecular and prognostic variables. In addition, we discuss enabling technologies, including virtual staining and interpretability methods, that support clinical integration. Finally, we address key challenges, including data heterogeneity, the need for prospective validation, and interdisciplinary collaboration. AI-powered, explainable morphological analysis has the potential to advance precision hematology and personalized patient management.
6 November 2024 in British Journal of Haematology